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https://doi.org/10.1016/j.celrep.2021.109433SUMMARYThe novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of
severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-
SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patientswere constructed and
recombinant antibody fragments (scFv) against the receptor-binding domain (RBD) of the spike protein were
selected by phage display. The antibody STE90-C11 shows a subnanometer IC50 in a plaque-based live
SARS-CoV-2 neutralization assay. The in vivo efficacy of the antibody is demonstrated in the Syrian hamster
and in the human angiotensin-converting enzyme 2 (hACE2) mice model. The crystal structure of STE90-C11
Fab in complex with SARS-CoV-2-RBD is solved at 2.0 Å resolution showing that the antibody binds at the
same region as ACE2 to RBD. The binding and inhibition of STE90-C11 is not blocked by many known
emerging RBD mutations. STE90-C11-derived human IgG1 with FcgR-silenced Fc (COR-101) is undergoing
Phase Ib/II clinical trials for the treatment of moderate to severe COVID-19.INTRODUCTION
The severe pneumonia COVID-19 (coronavirus disease 2019) is
a disease caused by the novel coronavirus severe acute respira-
tory syndrome-coronavirus-2 (SARS-CoV-2) and was described
at the end of 2019 in Wuhan, China (Lu et al., 2020; Zhou et al.,This is an open access article und2020). This new human pathogenic coronavirus is closely related
to the bat coronavirus RATG13, indicating an animal-to-human
transition (Shang et al., 2020a). The Spike (S) protein of SARS-
CoV-2 binds to the human zinc peptidase angiotensin-convert-
ing enzyme 2 (ACE2) as the main receptor for cell entry. The S
protein has two subunits: the N-terminal S1, harboring theCell Reports 36, 109433, July 27, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSreceptor binding domain (RBD), and the viral membrane-
anchored C-terminal S2 subunit, which is required for trimeriza-
tion and fusion of the virus and host membrane for viral entry
(Shang et al., 2020b; Starr et al., 2020; Walls et al., 2020;
Wang et al., 2020b;Wrapp et al., 2020; Yan et al., 2020). Blocking
of the RBD-ACE2 interaction by therapeutic antibodies as a
strategy to treat COVID-19 (Zhou and Zhao, 2020) is a promising
approach since the successful generation of neutralizing anti-
bodies against S1 and RBD was already demonstrated for
SARS-CoV and Middle East respiratory syndrome (MERS)
(Coughlin and Prabhakar, 2012; Widjaja et al., 2019; Zhu et al.,
2007). Some of the anti-SARS-CoV antibodies also showed
cross-reaction and cross-neutralization of SARS-CoV-2 (Huo
et al., 2020; Tian et al., 2020; Wang et al., 2020a).
Antibody phage display is a widely used in vitro technology to
select human antibody fragments for the development of thera-
peutic antibodies (Frenzel et al., 2016). Currently, 14 European
Medicines Agency- (EMA) or US Food and Drug Administration-
(FDA) approved antibodies were generated by antibody phage
display (Alfaleh et al., 2020). Human antibodies can be selected
from two kinds of antibody gene libraries: universal libraries and
immune libraries. Universal libraries, which have a naive, semi-
synthetic, or synthetic antibody gene repertoire, allow, in theory,
the selection of antibodies against any kind of molecule, while
immune libraries derived from immunized donors typically facil-
itate the antibody generation against the pathogen that affected
the donors (Bradbury et al., 2011; Frenzel et al., 2017; Kretzsch-
mar and von R€uden, 2002; K€ugler et al., 2018; Kuhn et al., 2016).
Immune phage display libraries from convalescent patients or
immunized human donors were used for the successful genera-
tion of antibodies against infectious diseases (Duan et al., 2009;
Rahumatullah et al., 2017; Trott et al., 2014; Wenzel et al., 2020a;
Zhang et al., 2003). Human antibodies were also selected
directly against SARS-CoV-2 using different approaches,
including single B cell cloning or antibody phage display
(Baum et al., 2020; Bertoglio et al., 2021; Kreer et al., 2020; Rob-
biani et al., 2020; Shi et al., 2020; Zeng et al., 2020).
Recently, several SARS-CoV-2 variants with mutations in the
RBD emerged. Here, most prominent are the B.1.1.7 (‘‘UK,’’
RBD mutation N501Y), B.1.351 (‘‘Southafrica,’’ K417N, E484K,
N501Y), and P1 (B.1.1.28.1) (‘‘Brazil,’’ K417T, E484K, N501Y)
(Rees-Spear et al., 2021). More recently other variants such as
B.1.429+B.1.427 (‘‘Southern California,’’ L452R) (Zhang et al.,
2021), B.1.526 (‘‘New York,’’ E484K, in some variants S477N
instead of E484K) (Annavajhala et al., 2021), B.1.258D (‘‘Czech,’’
N439K) (Brejová et al., 2021; Surleac et al., 2021), P2 (B.1.1.28.2)
(E484K) (Nonaka et al., 2021), P3 (B.1.1.28.3) (E484K, N501Y)
(Tablizo et al., 2021), B.1.1.33 (E484K) (Resende et al., 2021),
B.1.617 (‘‘India,’’ L452R, E484Q) (Ranjan et al., 2021), and other
variants such asB.1.525 (E484K) (Hodcroft et al., 2021) occurred.
In this work, immune phage display libraries from six COVID-19
convalescent patients were constructed and RBD-binding anti-
bodies have been selected, resulting in SARS-CoV-2-inhibiting
and -neutralizing antibodies. The crystal structure of the best
neutralizing candidate STE90-C11 in complex with wild-type
(WT)RBDwaselucidated. Togetherwith its uniquebindingpattern
that tolerates a large number ofRBDmutations, its properties sug-
gest itsuseasa therapeuticagent againstSARS-CoV-2 infections.2 Cell Reports 36, 109433, July 27, 2021RESULTS
Immune library construction
For the immune library construction, we collected blood samples
of 16 qRT-PCR-confirmed COVID-19 convalescent patients. To
analyze the immune answer, the sera of all patients were titrated
onRBD (Data S1A). Patients 1, 2, 5, 6, 9, and 14 showed the high-
est immunoglobulin G (IgG) titers against RBD and were chosen
for library construction. Peripheral blood mononuclear cells
(PBMCs) were isolated and CD19+/CD138+ plasma cells were
enriched by fluorescence-activated cell sorting (FACS) from
some of these samples. Both PBMCs and plasma cells were
used for library construction. Six individual libraries were con-
structed from the PBMCs of patients 2, 6, and 14, while 4 addi-
tional libraries weremade fromCD19+/CD138+ plasma cell pools
(pool 1: patients 2, 6, and 14; pool 2: patients 1, 5, and 9). All of the
libraries were constructed cloning kappa and lambda antibody
genes separately, resulting in diversities ranging from 0.7 3 107
to 1.7 3 108 estimated independent clones.
Antibody fragments were selected against SARS-CoV-2
Antibodies were selected by panning in microtiter plates against
SARS-CoV-2 S1 subunit using S1-S2 in the first panning round,
RBD in the second panning round, andS1-S2 in the third panning
round. This approach focused on the antibody selection on epi-
topes locatedwithin theRBDwhile being presented in the correct
conformation of the intact S protein trimer. The two plasma cell-
derived immune libraries were combined for kappa, and lambda,
respectively, and the panning was performed separately for
lambda and kappa libraries. All kappa and lambda libraries orig-
inating from the PBMCswere pooled together. The following sin-
gle-clone screening was performed by antigen ELISA in 96-well
microtiter plates (MTPs), using soluble monoclonal single-chain
variable fragment (scFv) produced by Escherichia coli. A total of
542 monoclonal hits were identified. DNA sequencing revealed
197 unique antibodies. The V gene combinations for kappa and
lambda (Data S1B) antibodies were analyzed. The most abun-
dantly used V genes were VH3-66, VK1D-39, and VL3-21. Anti-
body sequences that showed potential developability liabilities
(i.e., glycosylation sites or single cysteines in the complemen-
tarity-determining regions [CDRs]) were excluded from further
analysis. A total of 135antibodieswere re-cloned into the bivalent
scFv-Fc format and produced in Expi293F cell in 5-mL culture
scales, with yields ranging from 70 to 260 mg/L.
Screening for inhibition in a cell-based assay
To screen for SARS-CoV-2-blocking antibodies, an inhibition
assay was performed by flow cytometry on ACE2-expressing
EXPI293F cells, measuring direct competition between S1-S2
trimer and scFv-Fc antibodies. The entire S protein ectodomain
was used for this inhibition assay for optimal representation of
viral binding. In a first screening, the 135 antibodies were tested
at 1,500 nM S1-S2 (molar ratio antibody:S1-S2 30:1) (Figure 1).
Thirty antibodies that inhibited S1-S2 binding >80% were
selected for further analysis. The germline genes of these inhib-
iting scFv-Fcs are given in Table 1. VH3-66 was the most abun-
dantly used heavy-chain V gene of thewell-inhibiting scFv-Fc. All
VH3-66 derived antibodies had closely related variable domains
Figure 1. Inhibition of SARS-CoV-2 spike
protein binding cells (flow cytometry)
Inhibition prescreen of 135 scFv-Fc antibodies on
ACE2+ cells using 1,500 nM antibody and 50 nM
Spike protein (30:1 ratio). The antibodies selected
for detailed analysis are marked in colors. Bars
with a red background and crossed stripes indi-




OPEN ACCESSof heavy chains (VH) CDR amino acid (aa) sequence, while the
corresponding light chains were different.
Antigen binding and cell-based inhibition by IgG
The 30 antibodies were screened in a cytopathic effect (CPE)-
based neutralization screening assay (data not shown) to select
antibodies for further characterization as IgG. This assaywasper-
formedwith 250plaque-forming units (pfu)/well SARS-CoV-2 and
1 mg/mL (10 nM) scFv-Fc.CPE is characterizedby rounding and
detachment clearly visible in phase contrast microscopy upon
SARS-CoV-2 infection within 4 days, while uninfected cells main-tained an undisturbed confluent mono-
layer. The best neutralizing 19 scFv-Fc
were re-cloned and produced as human
IgG in 50-mL culture scales, with yields
ranging from 12 to 93 mg/L. Half-maximal
effective concentration (EC50) values of
binding to RBD, S1, or S1-S2 were deter-
mined (Figure 2) and are shown in Table
1. Antibodies STE90-C11, STE90-B2-
D12, STE94-F6, and STE94-H2 showed
EC50 values ranging between 0.2 and
0.5 nM on all of the antigens tested. Inhibi-
tionof ACE2bindingwasassessedat con-
centrations from 100 to 0.3 nM IgG using
10 nM RBD (Data S2A) or 500–1.5 nM
IgG using 50 nM S1-S2 Spike (Data S2B)
in the previously described cell-based in-
hibition assay (Bertoglio et al., 2021). The
extent of inhibition by STE90-C11 of both
RBD and S1-S2 was validated in a further
cellular assay with ACE2-expressing cells
(Data S3). The best antibodies showed
half-maximal inhibitory concentration
(IC50) values of 2.6–15 nM IgG for 50 nM
S1-S2 Spike, respectively, and 1–3 nM
IgG for 10 nMRBD (Table 1). For 50% inhi-
bition, thebestmolar ratioswere from0.02
to 0.3:1 (antibody binding site:antigen).
Antibodies from COVID-19 patient
libraries neutralize active SARS-
CoV-2 virus
To analyze the neutralization capacity of
the antibodies, the 19 IgGs were first
screened in a plaque titration assay using
active 15 pfu SARS-CoV-2 virus. The
antibody palivizumabwas used as a control antibody (Figure 3A).
The antibody STE90-C11 was chosen to be further analyzed. To
confirm its neutralizing activity, a plaque assay using 150 pfu
was performed and the determined IC50 was 0.56 nM in the
IgG format (Figure 3B).
STE90-C11 is specific for SARS-CoV-2 and binds most
RBD mutations, including B.1.617
A detailed characterization of the best neutralizer was performed
in regard to cross-reaction to other coronaviruses, binding to
known RBD mutations, and biochemical and biophysicalCell Reports 36, 109433, July 27, 2021 3
Table 1. Overview on inhibiting antibodies
Antibody name VH
Germinality
index VH (%) VL
Germinality
index VL (%)










PHE162-D2 IGHV4-31 98.9 IGLV1-40 98.5 3.3 3.9 7.5 160 3.20 34.0 3.40
STE90-A10 IGHV3-66 98.6 IGKV1-5 94.4 – – – – – – –
STE90-C11 IGHV3-66 98.6 IGKV1-9 100 0.2 0.2 0.3 2.56a 0.05a 0.99a 0.03a
STE90-D7 IGHV3-66 98.6 IGKV1-12 98.1 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
STE94-A1 IGHV3-66 98.6 IGLV1-40 100 n.d. n.d. n.d. 460 9.20 31.3 3.13
STE90-B1-A10 IGHV3-66 98.6 IGKV1-5 98.1 – – – – – – –
STE90-B1-B3 IGHV3-66 98.6 IGKV1-9 96.0 – – – 21.1 0.42 4.56 0.46
STE90-B1-B4 IGHV3-66 98.6 IGKV1D-39 92.5 – – – – – – –
STE90-B1-D6 IGHV3-53 97.7 IGKV1D-39 96.4 – – – 80.6 1.61 81.6 0.82
STE90-B2-A1 IGHV3-66 98.6 IGKV1D-39 92.8 1.4 2.6 5.2 620 12.4 19.3 1.93
STE90-B2-B3 IGHV3-66 98.6 IGKV1-5 100 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
STE90-B2-C5 IGHV3-66 98.6 IGKV1-5 100 n.d. n.d. n.d. 420 8.40 640 64.0
STE90-B2-D12 IGHV3-66 98.6 IGKV1-9 100 0.3 0.4 0.4 27.1 0.54 4.49 0.45
STE90-B2-E6 IGHV3-53 100 IGKV1D-39 98.1 – – – n.d. n.d. n.d. n.d.
STE90-B3-B10 IGHV3-66 98.6 IGKV1-5 100 n.d. n.d. n.d. 250 5.0 490 49.0
STE90-B3-H3 IGHV3-66 98.6 IGKV1D-12 100 – – – – – – –
STE91-B1-A10 IGHV3-66 98.6 IGLV3-1 89.4 – – – – – – –
STE91-B1-B3 IGHV3-66 98.6 IGLV3-21 100 – – – – – – –
STE91-B1-C4 IGHV3-66 98.6 IGLV3-1 85.9 – – – – – – –
STE91-C4 IGHV3-66 98.6 IGLV3-21 91.6 4 7.9 n.d. 36.4 0.73 7.15 0.72
STE91-D4 IGHV3-66 98.6 IGLV3-1 89.4 – – – – – – –
STE91-F6 IGHV3-66 98.6 IGLV1-40 100 2.3 3.8 5.9 30.0 0.60 5.99 0.60
STE94-B1-D1 IGHV3-66 98.6 IGLV3-21 95.0 1 0.9 2.5 15.5 0.31 3.09 0.31
STE94-B1-E12 IGHV3-66 98.6 IGLV3-1 85.0 0.4 0.7 1.6 11.5 0.23 2.49 0.25
STE94-B2 IGHV3-66 98.6 IGLV3-21 98.3 5.1 4.8 n.d. n.d. n.d. 5.55 0.56
STE94-B2-B1 IGHV3-66 98.6 IGLV1-40 100 1.2 2 7.5 140 2.80 3.35 0.34
STE94-B2-E11 IGHV3-66 98.6 IGLV1-51 91.3 4.7 7.7 n.d. 39.1 0.78 6.25 0.63
STE94-F6 IGHV1-69 96.3 IGKV1D-39 96.2 0.2 0.3 0.3 10.3 0.21 2.06 0.21
STE94-F12 IGHV3-66 98.6 IGLV3-21 93.3 0.7 1.2 2.4 43.7 0.87 8.74 0.87
STE94-H2 IGHV3-66 98.6 IGKV1-9 100 0.3 0.4 0.5 5.55 0.11 1.11 0.11
The EC50s were determined using 30 ng immobilized RBD-mFc, S1-mFc, and S1-S2-His (trimer) by ELISA. The IC50was determined by flow cytometry using 50 nM (in relation tomonomer) S1-S2
trimer, respectively 10 nMRBD and ACE2+ cells. Themolar ratio of antibody binding site:S1–S2 or RBD is given for 50% inhibition. EC50were calculated with GraphPad Prism version 6.1, fitting to
a 4-parameter logistic curve. IC50s were calculated with OriginPro using the Logistic5 Fit. –, not applicable. n.d., not determined.











































Figure 2. Determination of EC50 in ELISA
Binding in titration ELISA of the IgGs to RBD (fusion protein with murine Fc part), S1 (fusion protein with murine Fc part), or S1-S2 (fusion protein with His tag). An
unrelated antibody with murine Fc part (TUN219-2C1), human HEK293 cell lysate, BSA, and lysozyme were used as controls. Experiments were performed in
duplicate and means ± SEMs are given. EC50 were calculated with GraphPad Prism Version 6.1, fitting to a 4-parameter logistic curve.
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SARS-CoV-1, MERS-CoV, HCov-HKU1, HCoV-229E, and
HCoV-NL63 S proteins was tested by titration ELISA (Data
S4A). STE90-C11 bound specifically SARS-CoV-2 and did
not show any cross-reactions to other human-pathogenic
coronaviruses.
Because the first SARS-CoV-2 mutants in patients are being
identified (https://www.gisaid.org and Shi et al., 2020) and
more mutations within the RBD have been characterized to arise
under antibody selection pressure (Baum et al., 2020), S1 sub-
units harboring single-point mutations (PMs) described in GI-
SAID in the RBD were produced and the binding of STE90-C11
to those mutants was tested. In addition, a variant with 7 PMs
(V367F, N439K, G476, V483A, E484K, G485R and F486V) wasanalyzed (S1-7PM). The EC50 values of STE90-C11 are given in
Figure 4, and the corresponding ELISAs are given in Data
S4B–S4E, including further binding assays comparing STE90-
C11 to REGN10933, REGN10987, CR3022, and CB6. All S1 or
S1-S2 constructs were still able to bind recombinant ACE2
(Data S4F), indicating correct folding. The antibody STE90-C11
showed reduced binding to N501Y and lost binding to K417N/
K417T, but it was able to bind to all of the other investigated
RBD mutations, including a S1-7PM mutant and more relevant
to E484K, N439K, and L452R, which are the RBD mutations in
the emerging B.1.525, B.1.526, B.1.1.33, B.1.258, and
B.1.429/B.1.427 variants. Most important is the binding to
B.1.617 (L452R+E484Q), which is emerging in India and other
parts of the world. Subsequently, the inhibition of S1 binding toCell Reports 36, 109433, July 27, 2021 5
Figure 3. In vitro neutralization of authentic
SARS-CoV-2
(A) Neutralization screening of ~15 plaque-forming
units (pfu) SARS-CoV-2 by 19 anti-RBD SARS-CoV-
2 IgGs.
(B) STE90-C11 titration on ~150 pfu SARS-CoV-2 to
determine the IC50. Neutralization assays were
performed in triplicate; mean ± SEMs are given.
Palivizumab was used as isotype control in both




OPEN ACCESSACE2 for the RBD mutants bound best by STE90-C11 was
confirmed in the cell-based inhibition assays (Data S5). The inhi-
bition of B.1.617 was slightly better than the inhibition of the WT.
STE90-C11 is protective in vivo in the hamster challenge
model
The SARS-CoV-2 neutralizing effect of STE90-C11 was tested
in vivo in a Syrian hamster challenge model. In this model, ham-
sters were intranasally infected with 1 3 105 pfu genuine SARS-
CoV-2 and treated 2 h later with 3.7 or 37 mg/kg STE90-C11 or
with PBS in the control group. The virus titer in the lung of treated
animals showedadose-dependent reductionof viral loadondays
3 and 5 after infection (Figure 5A). The measured mean viral load
was 8.33 103 pfuwith 37mg/kg IgGcompared to 1.53 106 pfu in
the PBS control at day 3. The hamster model is further character-
ized by a rapid weight loss in the first days after SARS-CoV-2
infection but also rapid recovery of body weight from 1 week
post-infection on. Animals treated with the higher STE90-C11
dose showed a reduced loss of weight and a faster weight recov-
ery compared to the PBS control (Figure 5B).
STE90-C11 is protective in vivo in the transgenic ACE2
mice challenge model
The SARS-CoV-2 neutralizing effect of STE90-C11 was further
tested in vivo in the transgenic human ACE2 mice model
(K18hACE2). Mice were first treated with 6, 30, 60, or 120 mg/
kg STE90-C11 or with PBS in the control group. After 1 h, they
were inoculated intranasally with 1,000 or 2,000 pfu genuine
SARS-CoV-2 or with PBS in the control group. The virus titer
was measured with 4.7 3 104 pfu in the first experiment with
1,000 pfu and 7.4 3 105 pfu in the experiment with 2,000 pfu.
Only in the two experiments, one with 60 mg/kg and one with
6 mg/kg, was a remaining viral load of 5.6 3 102 and 3.1 3 102
pfu, respectively, detected. In all other mice treated with
STE90-C11, the virus was completely removed from the lungs
(Figures 5C and 5D). In the control group, a significant weight
loss was measured 4 days post-infection, which was not
observed in the groups with STE90-C11 treatment (Figure 5E).
SARS-CoV-2 escape mutant screening leads to
increased K417x but not N501x mutations
An in vivo escape mutant screening experiment was performed
according to Baum et al. (2020) to determine RBD mutants that
are not neutralized by STE90-C11. Here, serial dilutions of
STE90-C11 and palivizumab as the control antibody were used
to infect Calu-3 cells with active WT SARS-CoV-2. The superna-
tant with the propagated virus particles were used for the second6 Cell Reports 36, 109433, July 27, 2021round of neutralization and infection. After the second passage,
the viruses were analyzed by DNA sequencing. In the experiment
with STE90-C11, 4.7% of the remaining viruses wereWT, 81.9%
had the K417T mutations, 3.35 K417T+A475V, 0.3% A475V,
0.3% N481H, 0.12% N481Y, and 0.11% N501T. In the control
experiment with a non-related antibody and no selection pres-
sure, 89.9% of the remaining viruses were WT, 0.32% N481H,
0.14%K417T, 0.13%N501T, and 0.1%Q414K. This experiment
shows that the K417x mutation was not neutralized by STE90-
C11, but no selection pressure was found on the N501x muta-
tions, indicating a sufficient neutralization of these variants by
STE90-C11.
Biochemical characterization of STE90-C11
Aggregation propensity is an important quality parameter in ther-
apeutic antibody development. STE90-C11 showed no relevant
aggregation under normal conditions (pH 7.4, 4C in PBS), heat
stress conditions (pH 7.4, 45C, 24 h in PBS), and pH stress (pH
3, 24 h, room temperature [RT]) (Data S6A). A further test to
exclude polyreactivity was performed on different antigens
(DNA, lipopolysaccharide [LPS], lysozyme, and EXPI cell lysate)
with the FDA-approved antibody avelumab as control (Data
S6B). Here, STE90-C11 showed equal or less unspecificity
compared to avelumab. The monovalent affinity of STE90-C11
was determined by bio-layer interferometry (BLI) in three
different setups (Data S6C–S6E). In the first setup, RBD-mFc
was immobilized using anti-Fc capture tips, and the KD of
STE90-C11 in monovalent Fab format was determined to be
8.1 nM. In the second setup, the IgG was immobilized using a
Fab2G capture tip, and the KD of monovalent S1-His was deter-
mined to be 1.6 nM. In the third assay, the IgG was immobilized
using a protein A capture tip, resulting in a measured KD of
6.5 nM to S1-His, confirming that the affinity of STE90-C11 is
in the low nanomolar range. STE90-C11 did not bind to RBD
on immunoblots after treatment at 95C and SDS-gel separation
under reducing conditions, while it was able to detect RBD when
separated under non-reducing conditions heated either at 95C
or 56C (Data S6F). These data suggest that the antibody recog-
nizes a conformational epitope.
STE90-C11 binds at the ACE2-RBD interface
To get further insight into the neutralizing mechanism of STE90-
C11, a complex of STE90-C11 Fab and SARS-CoV-2 RBD (22-
kDa fragment) was prepared and subjected to crystallization
screening. X-ray diffraction images collected from the resulting
crystals yielded a dataset to an overall resolution limit of 2.0 Å
(Data S7A). After solving the structure bymolecular replacement,
Figure 4. Cross-reactivity analysis of STE90-C11
Binding to S1 or S1-S2 of different SARS-CoV-2 RBD mutations identified in
virus variants from COVID-19 patients analyzed by ELISA. The EC50 values are
given for each analyzed mutant. The corresponding ELISAs are given in Data
S4B–S4D. nd, not determinable. S1-7PM contains the 7 mutations V367F,
N439K, G476, V483A, E484K, G485R, and F486V.
Article
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OPEN ACCESSa model was built into the electron density (Figure 6). Figure 6A
shows the binding of STE90-C11 to RBD and Figure 6B shows
the binding of ACE2 to RBD. STE90-C11 binds SARS-CoV2
RBD with an interface area of 1,113 Å2 (Figure 6C; Data S7B).
Roughly 60% of this area can be contributed to the VH segment,
forming up to 10 hydrogen bonds at the same time and the re-
gion dominated by hydrophobic interaction (V99, A100, Y33,
and Y52) (Figure 6D). The remaining 40% are provided by the
variable domain of light chain (VL) segment contributing 8 addi-
tional hydrogen bonds to stabilize the interaction (Figure 6E). All
6 CDR loops contribute to the interaction between STE90-C11
Fab and SARS-CoV-2 RBD. The superposition of the RBDs of
the STE90-C11:SARS-CoV-2 RBD complex with a ACE2:-
SARS-CoV-2 RBD complex (Lan et al., 2020) resulted in a low
Ca root mean square distance of 0.532 Å (183 atoms), indicating
that the binding of STE90-C11 did not induce substantial
changes in the RBD. The superposition further revealed that
the neutralization mechanism of STE90-C11 is based on directly
competing for the ACE2 binding side, as the interaction inter-
faces on the RBD of both molecules almost completely overlap.
Further superposition of the STE90-C11:SARS-CoV-2 RBD
complexmodel onto cryoelectronmicroscopy (cryo-EM)models
of the whole SARS-CoV-2 S protein (Walls et al., 2020) indicate
that due to steric hindrance, STE90-C11-like ACE2 is expected
to bind only to the open conformation of the S protein (Data S7C).
DISCUSSION
For the treatment of COVID-19 but also to protect risk groups,
human anti-SARS-CoV-2 antibodies are a promising therapeutic
option. Human recombinant antibodies were successfully used
for the treatment of other viral diseases. The antibody mAb114
(ansuvimab-zykl) (Corti et al., 2016) and three-antibody cocktail
REGN-EB3 (atoltivimab/maftivimab/odesivimab) (Pascal et al.,
2018) were approved by the FDA in 2020 and showed a good ef-
ficiency in clinical trials against the Ebola virus, especially incomparison to remdesivir (Mulangu et al., 2019). For the treat-
ment of a severe respiratory infection of infants caused by the
respiratory syncytial virus (RSV), the antibody palivizumab is
approved by both EMA and FDA (vanMechelen et al., 2016; Sub-
ramanian et al., 1998). These anti-viral antibodies can be used as
a blueprint to develop therapeutic antibodies against SARS-
CoV-2. Currently, monoclonal antibodies against SARS-CoV-2
are selected by rescreening memory B cells from a SARS patient
(Pinto et al., 2020), selected from COVID-19 patients by single B
cell PCR (Cao et al., 2020; Shi et al., 2020) or FACS sorting (Kreer
et al., 2020), selected from transgenic mice and from patients by
single B cell FACS sorting (Hansen et al., 2020) or using phage
display with universal or patient libraries, including different anti-
body formats (Bertoglio et al., 2021; Chi et al., 2020; Li et al.,
2020; Liu et al., 2020; Ma et al., 2021; Noy-Porat et al., 2020; Par-
ray et al., 2020; Zeng et al., 2020).
In this work, antibody phage display immune libraries were
constructed using lymphocytes from six local convalescent
COVID-19 patients. A total of 197 unique antibodies were
selected against RBD. We intently focused on RBDs, aiming to
select antibodies that directly interfere with the interaction be-
tween S protein and ACE2, to avoid potential antibody-depen-
dent enhancement (ADE), especially in patients with severe
symptoms. ADE during coronavirus entry has been described
for both MERS (Wan et al., 2020) and SARS (Wang et al.,
2014). It is defined as ‘‘enhancement of disease severity in an
infected person or animal when an antibody against a patho-
gen...worsens its virulence by a mechanism that is shown to
be antibody-dependent’’ (Arvin et al., 2020). Furthermore, im-
mune dysregulation and lung inflammation was also caused by
anti-Spike antibodies in an acute SARS-CoV infection (Liu
et al., 2019). However, Quinlan et al. (2020) reported that animals
immunized with RBD SARS-CoV-2 did not mediate ADE. A ther-
apeutic antibody directed against RBD and the usage of a Fc
part that is not binding to Fc-g receptors (‘‘silent Fc’’) would
reduce the risk of ADE, in particular because ADE cannot be fully
predicted from in vitro studies or from animal models (Arvin et al.,
2020). Winkler et al. (2021) argue that an intact Fc part is needed
for optimal therapeutic protection. The ACTIV-3/TICO LY-
CoV555 Study Group et al. (2021) described no efficacy of LY-
COV-555 in hospitalized patients and also discussed ADE as a
potential explanation for the lacking efficacy. Because the role
of ADE is not fully deciphered in the case of SARS-CoV-2 (Lee
et al., 2020) and LY-CoV555 was not effective in patients with se-
vere symptoms, it is advisable that a silent Fc part be used to
address hospitalized patients with moderate to severe symp-
toms. Therefore, all assays with STE90-C11 IgGs were per-
formed with a silenced Fc part.
The selected anti-RBD antibodies were analyzed for
RBD::ACE2 inhibition in the scFv-Fc format. The advantage of
the IgG-like bivalent scFv-Fc format is that it speeds up analysis
by requiring only one cloning step and provides high expression
yields in a small-scale format (Bertoglio et al., 2021; Jäger et al.,
2013; Wenzel et al., 2020a). A total of 30 scFv-Fc antibodies in-
hibited the binding of the S protein to ACE2-expressing living
cells. Interestingly, the majority of the VH V genes of the selected
anti-RBD antibodies and 28 of these 30 inhibiting antibodies is
the VH3-66 V gene showed strong enrichment of this V gene inCell Reports 36, 109433, July 27, 2021 7
Figure 5. In vivo protection of STE90-C11 in a Syrian hamster challenge model and in the transgenic mice model
(A and B) Hamster model. Challenging of 9 animals per group with authentic SARS-CoV-2 and treatment with 3.7 mg/kg, 37 mg/kg STE90-C11, or PBS.
(A) Quantification of SARS-CoV-2 pfu from lung homogenates after SARS-CoV-2 challenge 3 days after infection (3 dpi) or 5 days (5 dpi).
(B) Body weight of hamsters after SARS-CoV-2 challenge from days 0 to 14. The mean values ± SEMs from 9 animals per group are given.
(C–E) K18hACE2 mice model: 2–4 animals per group were treated with 6, 30, 60, or 120 mg/kg STE90-C11 or with PBS as control and 1 h later infected with
authentic SARS-CoV-2.
(C and D) Quantification of SARS-CoV-2 pfu from lung homogenates after SARS-CoV-2 challenge 5 days post-infection (5 dpi). Two independent experiments are
shown. Experiment 1 (C) was performed with 2,000 pfu and experiment 2 (D) with 1,000 pfu SARS-CoV-2.




OPEN ACCESSthe immune response of COVID-19 patients against RBD. This is
in accordance with Cao et al. (2020), who found enriched use of
VH3-53 or VH3-66. VH3-53 and VH3-66 V-genes are closely
related. Robbiani et al. (2020) showed an enrichment of VH3-
30, VH3-53, and VH3-66 and Hansen et al. (2020) reported a
bias toward VH3-53. The VH3-53 and VH3-66 V-genes are
closely related. In contrast, Ju et al. (2020) identified mainly
VH1-2, VH3-48, and VH3-9 V-genes for their selected anti-
RBD antibodies from one patient and Brouwer et al. (2020) iden-
tified a strong enrichment of VH1-69, VH3-30 and VH1-24 in8 Cell Reports 36, 109433, July 27, 2021three patients, but also an enrichment of VH3-53 and VH3-66.
VH3-66 antibodies against RBD were also selected from the
naive HAL9/10 antibody gene libraries made long before the
SARS-CoV-2 outbreak (K€ugler et al., 2015) but not significantly
enriched (Bertoglio et al., 2021). The selected inhibiting anti-
bodies in our study (Table 1) have a high germinality index and
are therefore very similar to the not hypermutated human germ-
line, promising low immunogenicity when used as a therapeutic
agent. Only some light chains showed a major difference to their
closest related V gene. Kreye et al. (2020) also noted that the
Figure 6. The crystal structure of STE90-C11 in complex with SARS-CoV-2-RBD
(A and B) The structure of the complex between RBD (green) and STE90-C11 (A; heavy chain: yellow; light chain: pale yellow) or ACE2 (B; red; PDB: 6M0J; Lan
et al., 2020) depicted in illustrative form after superposition of the RBD.
(C) Surface representation of the RBDwith the binding surface (cutoff 4 Å) of STE90:C11 in yellow and of ACE2 in red. The competitive binding surface is in orange.
(legend continued on next page)






OPEN ACCESSantibodies they selected from COVID-19 patients were very
close to the germline genes. Interestingly, the VH V genes of
these immune libraries are closer to their germline compared
to the anti-RBD antibodies selected from the naive HAL9/10 anti-
body gene libraries (Bertoglio et al., 2021).
In the cell-based inhibition assay, some of the antibodies
showed a molar antibody:spike monomer ratio lower than 1:1.
Similar behavior was also found by Bertoglio et al., (2020) and
may be explained by the observation that three RBDs on the
same S trimer can be in different conformations (‘‘up’’ and
‘‘down’’), while only the RBDs in ‘‘up’’ positions are able to
bind ACE2 (Walls et al., 2020), and therefore, the ‘‘down’’
RBDs are not fully accessible.
Themonovalent affinity of STE90-C11wasmeasuredwith 1.6–
8.1 nM, depending on the BLI setup. This is in the same range as
BD-368-2, with 0.82 nM affinity to RBD (Cao et al., 2020), 3.3 nM
for REGN10933 in the setup with the monovalent RBD (Hansen
et al., 2020), 70 nM for B38 (Wu et al., 2020), or 0.8–4.7 nM for
CB6 (Shi et al., 2020).
The analysis of the binding STE90-C11 to other human coro-
naviruses showed specificity for SARS-CoV-2. Comparison be-
tween the epitope of STE90-C11 and other published antibodies
(Figure 5F) revealed that it binds in the same region as CB6 (Shi
et al., 2020) and B38 (Wu et al., 2020). The selectivity of STE90-
C11 and CB6 for SARS-CoV-2 over SARS-CoV RBD can mainly
be attributed to the interaction with residues 473–476, as they
are not involved in ACE2 binding, and SARS-CoV RBD folds
into a different conformation of this loop, causing steric hin-
drance for antibody binding (Lan et al., 2020).
In addition to the in vitro neutralization of authentic SARS-
CoV-2, the in vivo efficacy of STE90-C11 was demonstrated in
the Syrian hamster challenge model (Kreye et al., 2020) and in
the model using transgenic mice with hACE2 receptor (Wu
et al., 2020) in a dose-dependent manner.
The binding of STE90-C11 to S1 containing RBD mutations
observed in strains from COVID-19 patients was analyzed,
showing binding to most variants. As the cell-based inhibition
analysis demonstrates, STE90-C11 is able to inhibit most
analyzed mutants, validating a tolerance for RBD mutations.
REGN10933 (Hansen et al., 2020), which is also binding at the
RBD-ACE2 interface, showed a loss of neutralization in an assay
using pseudoviral particles for the F486V and a reduced neutral-
ization for both G485D and E484Kmutations (Baum et al., 2020).
Loss of binding to F486A is also described for VH-Fc ab8 (Li
et al., 2020). In the epitope analysis, REGN10933 has more mo-
lecular interactions within the region aa483–aa486 compared to
STE90-C11. Currently, the variant B.1.1.7 is widespread and
STE90-C11 has reduced binding to N501Y and lost binding to(D and E) Detailed view of the interactions between RBD and the heavy chain (D
dashed yellow lines and residues with alternate conformations are marked with a
(F) Sequence alignment of RBD. Depicted is a part of the sequence alignment of th
residues are depicted as bold blue letters. Under the alignment contacts between
(PDB: 7B3O), CB6 (PDB: 7C01; Shi et al., 2020), B38 (PDB: 7BZ5; Wu et al., 202
6XDG; Hansen et al., 2020), and BD-368-2 (PDB: 7CHF; Cao et al., 2020) are mar
distance under 4 Å and a red letter indicates a distance under 3.2 Å between non
residues often exchanged in the RBD of SARS-CoV-2, which were tested for thei
CNS (Br€unger et al., 1998) and the representation was prepared using ESPript (R
10 Cell Reports 36, 109433, July 27, 2021mutants with the K417N/T mutations in combination with
N501Y, which occur in B.1.351 and B.1.1.28.1 variants. The
structure suggests that the exchange N501Y may push the light
chain CDR1 loop of the antibody further away, while the ex-
change of K417N/T leads to an abolishment of a salt bridge to
D101 of the heavy chain, similar to observations done for
COVOX-269 and COVOX-222, respectively (Dejnirattisai et al.,
2021; Supasa et al., 2021). In COVOX-269, binding to the
RBD-N501Y leads to a conformational change of light-chain
CDR3 loop around Y94. In the escape mutant experiment, no
N501x mutants were enriched, indicating a sufficient neutraliza-
tion of the N501x but not K417x mutation.
On the other hand, STE90-C11 binds strongly to the RBD mu-
tations in the emerging SARS-CoV-2 variants B.1.429/B.1.427
(L452R), B.1.526 (E484K or S477N), B1.258D (N439K), B.1.525
(E484K), B.1.1.28.2 (E484K), B.1.1.33 (E484K), and B1.617
(L452R, E484Q). These variants are emerging; for example, the
frequency of B.1.429+B.1.427 reached 40% in January 2021
(Zhang et al., 2021) or B.1.258 with 59% in the samples
sequenced in Czech in the last 3 months of 2020 (Brejová
et al., 2021). B1.617 (L452R, E484Q) and derivates have super-
seded B.1.1.7 in India, and the prevalence of this variant was
the majority of all of the sequenced viruses at the end of April
2021 (https://outbreak.info/location-reports?loc=IND). We hy-
pothesize that STE90-C11 still binds to most analyzed RDB mu-
tants because of both the wide interface area of 1,133 Å2 and the
extensive light-chain contacts that may compensate the ex-
change of several amino acids. The calculated interface area
of STE90-C11 VL is more than twice the area of REGN10933
and REGN10987 and slightly larger compared to CB6 or
CR3022 (Data S7B).
In summary, the patient-derived SARS-CoV-2 neutralizing
anti-RBD antibody STE90-C11 binding to the RBD-ACE2 inter-
face maintains high similarity to the human germline V genes
VH3-66, the same family of many isolated anti-SARS-CoV-2
neutralizing antibodies. STE90-C11 is tolerant to most known
RBD mutants, especially those of the mutants B.1.429/
B.1.427, B.1.526, B1.258D, B.1.535, B.1.617, and B.1.1.33,
which are currently emerging. A Phase Ib/II clinical trial with a
full human IgG1 variant with FcgR-silenced Fc STE90-C11
(COR-101) was started in April 2021 (ClinicalTrials.gov ID:
NCT04674566) to assess the safety and efficacy of COR-101
in hospitalized patients with moderate to severe COVID-19.
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(Continued on next page)
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Reagent or Resource Source Identifier
Laemmli sample buffer Laemmli, 1970 N/A
5-Brom-4-Chlor-3-Indolyl-Phosphat/Nitro
Tetrazolium Blue Chloride
Thermo Fisher Scientific Cat#B6149
CHO CD efficient feed A Thermo Fisher Scientific Cat#A1023401
ExCell 405 serum-free medium Sigma Cat#14405C
2,3-(R,R)-butandiol Alfa Aeser Cat#513-85-9
Critical commercial kits
Direct-zol RNA Miniprep Plus Kit Zymo Research Cat#R2072
NucleoBond Xtra Midi Kit Macherey-Nagel Cat#12798402
NucleoSpin Gel and PCR Clean-up Kit Macherey-Nagel Cat#11992242
NucleoSpin Plasmid EasyPure Macherey-Nagel Cat#15162537




Crystal structure of STE90-C11 in complex
with SARS-CoV-2-RBD
This paper PDB 7B3O
Oligonucleotides
Primer set for VH and VL amplification (Wenzel et al., 2020b) N/A
Recombinant DNA
Spike protein (RBD; S1; S1-S2; N) Thermo Fisher/Gene Art GenBank: MN908947
ACE2 Thermo Fisher/Gene Art GenBank: NM021804.3
Software and algorithms
OrginPro (2019) OrginLab N/A
GraphPad Prism 6.1 GraphPad https://www.graphpad.com
VBASE MRC Centre for Protein Engineering https://www2.mrc-lmb.cam.ac.uk/vbase/
VBASE2 (Mollova et al., 2010) www.vbase2.org
DataGraph (4.5.1) DataGraph https://www.visualdatatools.com/
DataGraph/
IncuCyte S3 GUI Sartorius N/A
Phenix (Liebschner et al., 2019) www.phenix-online.org
BD FACS Chorus BD N/A
PyMol Schrödinger LLC www.pymol.org/2/
PISA European Bioinformatics Institute https://www.ebi.ac.uk/pdbe/
prot_int/pistart.html
Octet qKe Data Analysis HT 11.0 Fortebio/Sartorius N/A
Other
Äkta Go/Äkta Pure Cytiva N/A
Profinia System BIO-RAD N/A
Precision XS microplate sample processor BioTek N/A
Sartorius IncuCyte S3 Sartorius N/A
BD FACSMelody Cell Sorter BD N/A
Octet qKe Fortebio/Sartorius N/A
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All requests for resources and reagents should be directed to the Lead Contact author. This includes antibodies, plasmids and pro-
teins. All reagents are available on request after completion of a Material Transfer Agreement.
Data and code availability
The structure data and the antibody sequence of COR-101 is available at PDB 7B3O. This paper does not report original code. Any
additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
Additional resources
The clinical trial Ib/II studies are registered at ClinicalTrials.gov (ID: NCT04674566).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
For the generation of human immune antibody libraries against SARS-CoV-2, blood from COVID-19 convalescent patients were
collected from local hospitals. This was performed in accordance with the Declaration of Helsinki. All the voluntary donors were
informed about the project and gave their consent. The use of blood samples for the development of antibody phage display libraries
was approved by the ethical committee of the Technische Universität Braunschweig (Ethik-Kommission der Fakultät 2 der TU
Braunschweig, approval number FV-2020-02). The donors have given their consent for study publication. The donors included
both sex and were older than 18 years. A control serum was obtained from LADR Braunschweig.
METHOD DETAILS
Production of antigens in insect cells
The antigens were produced and purified as described before (Bertoglio et al., 2021; Korn et al., 2020). In brief, different domains or
subunits of the Spike protein (GenBank: MN908947) were produced Baculovirus-free in High Five cells (Thermo Fisher Scientific,
Schwerte, Germany) by transient transfection. High Five cells were cultivated at 27C, 110 rpm in EX-CELL 405media (Sigma Aldrich,
Munich, Germany) and kept at a cell density between 0.3 – 5.5 x106 cells/mL. For transfection cells were centrifuged and resus-
pended in fresh media to a density of 4x106 cells/mL and transfected with 4 mg plasmid/mL and 16 mg/mL of PEI 40 kDa (Polyscien-
ces). After 4 h to 24 h after transfection cells were diluted to a final density of 1x 106 cells/mL. At 48 h after transfection, the culture
volume was doubled. Cell supernatant was harvested five days after transfection in a two-step centrifugation (4 min at 180xg and
20 min at above 3500xg) and 0.2 mm filtered for purification.
Protein purification
Protein purification was performed as described before (Bertoglio et al., 2021) depending on the production scale in either 24 well
filter plate with 0.5 mL resin (10 mL scale) or 1 mL column on Äkta go (Cytiva), Äkta Pure (Cytiva) or Profinia System (BIO-RAD). Mab-
Select SuRe or HiTrap Fibro PrismA (Cytiva) was used as resin for Protein A purification. For His-tag purification of Expi293F super-
natant HisTrap FF Crude column (Cytiva) and for His-tag purification of insect cell supernatant HisTrap excel column (Cytiva) was
used. All purifications were performed according to the manufacturer’s manual. Indicated antigens were further purified by size
exclusion chromatography by a 16/600 Superdex 200 kDa pg (Cytiva). All antigens, antibodies and scFv-Fc were run on Superdex
200 Increase 10/300GL (Cytiva) on Äkta or HPLC (Techlab) on an AdvanceBio SEC 300Å 2.7 mm, 7.8x300 mm (Agilent) for quality
control.
Serum ELISA
For COVID-19 convalescent serum analysis, sera were titrated in 11 steps (dilution ratio 1:O3) on 100 ng/well of RBD-His. As unspe-
cificity controls, sera were tested on 100 ng/well BSA. All immobilization steps were performed in 0.05 M carbonate buffer (pH 9.6).
Serum IgGs were detected using goat-anti-hIgG(Fc)-HRP (1:70,000, A0170, Sigma). Titration assays were performed in 96 well mi-
crotiter plates (Costar) .
COVID-19 convalescent patient library construction
For the generation of human immune antibody libraries against SARS-CoV-2, blood from 6 donors showing a good antibody titer
against RBD was used (Data S1A). The library construction was performed as described previously with minor modifications (K€ugler
et al., 2018). In brief, the peripheral blood mononuclear cells (PBMC) were extracted from the blood via Ficoll (GE Healthcare, Frei-
burg, Germany) and RNA isolated with TRIzol LS reagent (Life Technologies, Carlsbad, USA) and Direct-zol RNA Miniprep Plus kit
(Zymo Research, Freiburg, Germany). For the plasma B cell sorted library, plasma B cells were double-stained with mouse
a-CD19 APC-conjugated (MHCD1905, Thermo Fisher Scientific, Schwerte, Germany) and mouse a-CD138 (FITC conjugated) anti-
body (DL-101, BioLegend, San Diego, USA), sorted via FACSMelody (BD, Franklin Lakes, USA). Sorted cells were directly collected
in TRIzol LS reagent and the RNA was extracted as indicated above. RNA was converted into cDNA using Superscript IV (Thermo
Fisher Scientific, Waltham, USA) according to the manufacturer’s instructions. Library construction was achieved as describedCell Reports 36, 109433, July 27, 2021 e3
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light chain were used to amplify antibody genes from the cDNA. These resulting PCR products were purified and again amplified with
primers adding specific restriction sites for further cloning into the E. coli expression vector pHAL52. The vector pHAL52 is derived
from the vector pHAL30 (K€ugler et al., 2015) with an AscI restriction site in the VL stuffer and a SalI restriction site in the VH stuffer for
removal of uncut vector backbone. First, the light chain was cloned between the restriction sites MluI-HF and NotI-HF. In a second
step the VH chain was cloned with the restriction sites HindIII-HF and NcoI-HF into previously cloned pHAL52-VL, additionally di-
gested with AscI. The efficiency of library cloning was tested by colony PCR and the rate of complete scFv insertion was determined.
The libraries were packaged with Hyperphage (Rondot et al., 2001; Soltes et al., 2007). Antibody phage were precipitated with PEG-
NaCl and resuspended in phage dilution buffer (10 mM TrisHCl pH7,5, 20 mM NaCl, 2 mM EDTA). Resulting phage titer was deter-
mined by infection of E. coli XL1 blue MRF’.
Antibody selection using phage display
Antibody selection was performed as described previously with modifications (Russo et al., 2018). In brief, 5 mg of of S1-S2-His or
RBD-His (produced in High Five cells) was diluted in carbonate buffer (50 mMNaHCO3/Na2CO3, pH 9.6) and coated onto the wells of
a High binding 96 well microtiter plate (High Binding, Costar) at 4C overnight. Next, the wells were blocked with 350 mL 2%MBPST
(2% (w/v) milk powder in PBS; 0.05% Tween20) for 1 h at RT and then washed 3 times with PBST (PBS; 0.05% Tween20). Before
adding the libraries to the coated wells, the libraries (5x1010 phage particles) were preincubated with 5 mg of an unrelated scFv-
Fc and 2% MPBST on blocked wells for 1 h at RT, to deprive libraries of human Fc fragment binders. The libraries were transferred
to the antigen coatedwells, incubated for 2 h at RT. After 10washes, bound phagewere elutedwith 150 mL trypsin (10 mg/mL) at 37C,
30 minutes and used for the next panning round. The eluted phage solution was transferred to a 96 deep well plate (Greiner Bio-One,
Frickenhausen, Germany) and incubated with 150 mL E. coli TG1 (OD600 = 0.5) first for 30 min at 37
C, then 30 min at 37C and
650 rpm to infect the phage particles. 1 mL 2xYT-GA (1.6% (w/v) Tryptone; 1% (w/v) Yeast extract; 0.5% (w/v) NaCl (pH 7.0),
100 mM D-Glucose, 100 mg/mL ampicillin) was added and incubated for 1 h at 37C and 650 rpm, followed by addition of 1x1010
cfu M13KO7 helper phage. Subsequently, the infected bacteria were incubated 30 min at 37C followed by 30 min at 37C and
650 rpm before centrifugation for 10 min at 3220xg. The supernatant was discarded and the pellet resuspended in fresh 2xYT-AK
(1.6% (w/v) Tryptone; 1% (w/v) Yeast extract; 0.5% (w/v) NaCl (pH 7.0), 100 mg/mL ampicillin, 50 mg/mL kanamycin). The antibody
phage were amplified overnight at 30C and 650 rpm and used for the next panning round. In total four panning rounds were per-
formed. In each round, the stringency of the washing procedure was increased (20x in panning round 2, 30x in panning round 3)
and the amount of antigen was reduced (2.5 mg in panning round 2, 1.5 mg in panning round 3). After third panning round single clones
were analyzed for production of RBD specific scFv by screening ELISA.
Screening of monoclonal recombinant binders using E. coli scFv supernatant
Soluble antibody fragments (scFv) were produced in 96-well polypropylene MTPs (U96 PP, Greiner Bio-One) as described before
(Russo et al., 2018; Wenzel et al., 2020a). Briefly, 150 mL 2xYT-GA was inoculated with the bacteria bearing scFv expressing phag-
emids. MTPs were incubated overnight at 37C and 800 rpm in a MTP shaker (Thermoshaker PST-60HL-4, Lab4You, Berlin, Ger-
many). A volume of 180 mL 2xYT-GA in a PP-MTP well was inoculated with 20 mL of the overnight culture and grown at 37C and
800 rpm for 90 minutes (approx. OD600 of 0.5). Bacteria were harvested by centrifugation for 10 min at 3220xg and the supernatant
was discarded. To induce expression of the antibody genes, the pellets were resuspended in 200 mL 2xYT supplementedwith 100 mg/
mL ampicillin and 50 mM isopropyl-beta-D-thiogalacto-pyranoside (IPTG) and incubated at 30C and 800 rpm overnight. Bacteria
were pelleted by centrifugation for 20 min at 3220xg and 4C.
For the ELISA, 100 ng of antigen was coated on 96 well microtiter plates (High Binding, Costar) in PBS (pH 7.4) overnight at 4C.
After coating, the wells were blocked with 2%MPBST for 1 h at RT, followed by three washing steps with H2O and 0.05% Tween20.
Supernatants containing secreted monoclonal scFv were mixed with 2%MPBST (1:2) and incubated onto the antigen coated plates
for 1 h at 37C followed by three H2O and 0.05%Tween20washing cycles. Bound scFv were detected usingmurinemAb 9E10which
recognizes the C-terminal c-myc tag (1:50 diluted in 2% MPBST) and a goat anti-mouse serum conjugated with horseradish perox-
idase (HRP) (A0168, Sigma) (1:42000 dilution in 2%MPBST). Bound antibodies were visualizedwith tetramethylbenzidine (TMB) sub-
strate (20 parts TMB solution A (30 mMPotassium citrate; 1% (w/v) Citric acid (pH 4.1)) and 1 part TMB solution B (10 mM TMB; 10%
(v/v) Acetone; 90% (v/v) Ethanol; 80 mMH2O2 (30%)) were mixed). After stopping the reaction by addition of 1 N H2SO4, absorbance
at 450 nmwith a 620 nm referencewasmeasured in an ELISA plate reader (Epoch, BioTek). Monoclonal binders were sequenced and
analyzed using VBASE2 (www.vbase2.org) (Mollova et al., 2010) and possible glycosylation positions in the CDRS were analyzed
according Lu et al. (2019.
ScFv-Fc and IgG production
Unique scFv sequences isolated by antibody-phage display were subcloned into pCSE2.7-hIgG1-Fc-XP using NcoI/NotI (New En-
gland Biolabs, Frankfurt, Germany) for mammalian production in Expi293F cells as scFv-Fc (Wenzel et al., 2020a). For IgG produc-
tion, the variable domains were recloned into the IgG vectors human IgG1 format by subcloning of VH in the vector pCSEH1c (heavy
chain) and VL in the vector pCSL3l/pCSL3k (light chain lambda/kappa) (Steinwand et al., 2014) adapted for Golden Gate Assembly
procedure with Esp3I restriction enzyme (New England Biolabs, Frankfurt, Germany). For the antibodies CB6 (pdb 7C01), CR3022e4 Cell Reports 36, 109433, July 27, 2021
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were ordered as GeneArt Strings DNA fragments (Thermo Fisher Scientific, Schwerte, Germany) and recloned in the above indicated
vectors. A ‘‘silenced’’ Fc part with following point mutations described Armour et al. (1999) and Shields et al. (2001) were used:
E233P, L234V, L235A, deletion of G236, D265G, A327Q and A330S. Expi293F cells were cultured at 37C, 110 rpm and 5% CO2
in GIBCO FreeStyle F17 expression media (Thermo Fisher Scientific) supplemented with 8 mM Glutamine and 0.1% Pluronic F68
(PANBiotech). At the day of transfection cell density was between 1.5 - 2x106 cells/mL and viability at least above 90%. For formation
of DNA:PEI complexes 1 mg DNA/mL transfection volume and 5 mg of 40 kDa PEI (Polysciences) were first diluted separately in 5%
transfection volume in supplemented F17 media. DNA (1:1 ratio of the vectors for IgG production) and PEI was then mixed and incu-
bated 25 min at RT before addition to the cells. 48 h later the culture volume was doubled by feeding HyClone SFM4Transfx-293
media (GE Healthcare) supplemented with 8 mM Glutamine. Additionally, HyClone Boost 6 supplement (GE Healthcare) was added
with 10% of the end volume. One week after transfection supernatant was harvested by 15 min centrifugation at 1500xg.
Inhibition of S1-S2 and RBD binding to ACE2 expressing cells using flow cytometry
The inhibition tests in flow cytometry on EXPI293F cells were performed based on a previously published protocol (Bertoglio et al.,
2021). Briefly, Expi293F cells were transfected according to the protocol above using pCSE2.5-ACE2fl-His and 5% eGFP plasmid.
Two days after transfection, purified S1-S2-His was labeled using Monolith NTTM His-Tag Labeling Kit RED-tris-NTA (Nanotemper)
according to themanufacturer’s protocol. In this setup 50 nMantigenwas incubatedwithmin. 1 mMof different scFv-Fc and the ACE2
expressing cells. The resulting median antigen fluorescence of GFP positive living single cells was measured. For comparison of the
different scFv-Fc first the median fluorescence background of cells without antigen was subtracted, second it was normalized to the
antigen signal where no antibody was applied. ScFv-Fc showing an inhibition in this first setup were further titrated as IgGs (max.
500 nM- 0.5 nM) on S1-S2-His, S1-His or on RBD-mFc (max. 100 nM-0.1 nM). S1-His and the corresponding mutants were detected
with mouse anti-penta His (QIAGEN) and goat anti-mFc APC-conjugated antibody (Dianova). RBD-mFc was detected directed with
the goat anti-mFc APC-conjugated antibody (Dianova). Measurements were performed with MACSQuant Analyzer (Milteny Biotech)
(Data S2). The IC50 was calculated using the equation f(x) = Amin+(Amax-Amin)/(1+(x0/x)̂ h)̂ s and parameters from OriginPro (2019).
Dose dependent binding of IgG in titration ELISA
For titration ELISA, purified IgGswere titrated from 3.18 mg/mL- 0.001 ng/mL on 30 ng/well of the following antigens: S1-S2-His (High
Five cell produced), RBD-mFc (High Five cell produced), S1-mFc (High Five cell produced) and TUN219-2C1-mFc (as control for un-
specific Fc binding). In addition, all scFv-hFc were also tested only at the highest concentration (3.18 mg/mL) for unspecific cross-
reactivity on Expi293F cell lysate (104 cells/well), BSA (1% w/v) and lysozyme. IgGs were detected using goat-anti-hIgG(Fc)-HRP
(1:70000, A0170, Sigma). Titration assays were performed using 384 well or 96 well microtiter plates (Greiner Bio-One) using Preci-
sion XS microplate sample processor (BioTek), EL406 washer dispenser (BioTek) and BioStack Microplate stacker (BioTek). EC50
were calculated with by GraphPad Prism Version 6.1, fitting to a four-parameter logistic curve. Titration ELISAs on other coronavi-
ruses and S1-HIS mutants were performed as described above.
Screening and titrating monoclonal antibodies for SARS-CoV-2 neutralization in cell culture
VeroE6 cells (ATCCCRL-1586) were seeded at a density of 6*104/well onto cell culture 96-well plates (Nunc, Cat.#167008). Two days
later, cells reached 100% confluence.
For titration, antibodies were diluted in 1/O10 steps and mixed with a fixed inoculum of SARS-CoV-2/M€unster/FI110320/1/2020
(kind gift of Stephan Ludwig, University of M€unster, Germany) (10-20, respectively 100-150 pfu) in a total volume of 500 ml of Vero
E6 medium (DMEM, 10% FCS, 2 mM glutamine, penicillin, streptomycin). After one hour incubation at 37C, cells were infected
with the antibody/virus mix, incubated for one hour and then overlaid with Vero E6 medium containing 1.5%methyl-cellulose. Three
days postinfection, wells were imaged using a Sartorius IncuCyte S3 (4x objective, whole-well scan) and plaques were counted from
these images. Image data was quantified with the IncuCyte S3 GUI tools measuring the decrease of confluence concomitant with the
cytopathic effect of the virus in relation to uninfected controls and controls without antibody and analyzed with Origin using the Lo-
gistic5 fit.
Specificity assay
To test specificity of the antibody candidates an ELISA on DNA, LPS, lysozyme and cell lysate was performed under standard con-
ditions (see above). In brief, 10 mg/mL of the respective antigen was immobilized on 96 well microtiter plates (High binding, Costar) in
PBS (pH 7.4) overnight at 4C. After blocking 10 mg/mL of STE90-C11 IgG, Avelumab, Palivizumab and IVIG respectively were incu-
bated and later detected using goat-anti-hIgG(Fc)-HRP (1:70000, A0170, Sigma). TMB reaction took place for 30 min and absor-
bance at 450 nm with a 620 nm reference was measured in an ELISA plate reader (Epoch, BioTek). All signals were normalized to
the absorbance of Avelumab.
Analytical size exclusion chromatography (SEC)
All purified antigens and indicated antibodies were run on Superdex 200 Increase 10/300GL column (Cytiva) on Äkta pure system
(Cytiva) according to the manufactures protocol.Cell Reports 36, 109433, July 27, 2021 e5
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The affinity was measured by Bio-Layer Interferometry in three different assays using the Octet qKe (Fortebio/Sartorius GmbH, Göt-
tingen, Germany).
In the first assay, anti-Mouse Fc-Capture (AMC) sensors were activated for 10min in PBS. After that, the sensors were equilibrated
in assay buffer (PBS containing 1%BSA and 0.05% Tween 20) for 60 s before RBD-mFc (Sino Biologicals) was loaded onto the sen-
sors at 10 mg/ml for 180 s. After a stable baselinemeasurement was established (60 s), antigen-loaded sensors were transferred to an
8-point antibody dilution series (500, 150, 50, 15, 5, 1.5, 0.5 and 0 nM). Association of the Fab antibody to the antigen was measured
for 300 s. After that, the sensors were transferred into assay buffer were the dissociation was measured for 900 s. Significant binding
of the antibody to an unloaded sensor was not detected. For data analysis, the reference measurement (0 nM) was subtracted from
the other measurements and data traces ranging from 150 to 1.5 nM were used for modeling of the kinetic data using a 1:1 binding
model (Data S6C).
In the second assay, anti-human Fab (FAB2G) sensors were activated for 10min in PBS. After that, the sensors were equilibrated in
assay buffer (PBS containing 1%BSA and 0.05% Tween 20) for 60 s before the IgG antibody was loaded onto the sensors at 2.5 mg/
ml for 180 s. After a stable baseline measurement was established (60 s), antibody-loaded sensors were transferred to an 8-point S1-
HIS antigen dilution series (500, 150, 50, 15, 5, 1.5, 0.5 and 0 nM). Association of the S1 antigen to the antibody wasmeasured for 300
s. After that, the sensors were transferred into assay buffer were the dissociation was measured for 900 s. Significant binding of the
antigen to an unloaded sensor was not detected. For data analysis, the referencemeasurement (0 nM) was subtracted from the other
measurements and data traces ranging from 50 to 5 nM were used for modeling of the kinetic data using a 1:1 binding model in the
Data Analysis HT 11.0 software tool (Data S6D).
In the third assay, protein A sensors were activated for 10 min in PBS. Before use, the sensors were regenerated for 5 cycles in
10 mMGlycine buffer (pH2.0) followed by neutralization in PBS. Each step was performed for 5 s. After that, the regenerated sensors
were equilibrated in assay buffer (PBS containing 1%BSA and 0.05%Tween 20) for 60 s before the IgG antibodywas loaded onto the
sensors at 2.5 mg/ml for 180 s. After a stable baselinemeasurement was established (60 s), antibody-loaded sensors were transferred
to an 8-point S1-HIS antigen dilution series (500, 150, 50, 15, 5, 1.5, 0.5 and 0 nM). Association of the S1 antigen to the antibody was
measured for 300 s. After that, the sensors were transferred into assay buffer were the dissociation was measured for 900 s. Signif-
icant binding of the antigen to an unloaded sensor was not detected. For data analysis, the reference measurement (0 nM) was sub-
tracted from the other measurements and data traces ranging from 50 to 0.5 nMwere used formodeling of the kinetic data using a 1:1
binding model (Data S6E).
Immunoblot analysis
For the immunoblot analysis RBD-His was disrupted either by incubation for 10 minutes at 56Cwithout b-Mercaptoethanol, at 95C
without b-Mercaptoethanol or at 95C in Laemmli sample buffer (Laemmli, 1970) with b-Mercaptoethanol. RBD was separated by
12% SDS-PAGE and blotted onto a nitrocellulose membrane (Amersham Protan 0.2 mm NC, GE HealthCare). The membrane was
blocked with 2% M-PBST for 1 h at RT. For the detection of RBD-His, 10 mg/mL STE90-C11 IgG was used. For control, RBD-His
(95C + b-Mercaptoethanol) was detected with 2mg/mL mouse anti-His (Dia-900-200, Dianova, Hamburg, Germany) for 1.5 h at
RT. After 3x washing with PBST the secondary antibody goat anti-human Fc AP conjugated (1:20,000, Jackson ImmunoResearch,
Cambridge House, UK) was used for the detection of STE90-C11 and goat anti-mouse IgG AP conjugated (1:30,000, 115-055-071,
Dianova) was used for the anti-His antibody and incubated for 1 h. Finally, themembrane waswashed 2xwith PBST and 4xwith PBS.
Staining and visualization of specific proteins was performed with 5-Brom-4-Chlor-3-Indolyl-Phosphat/Nitro Tetrazolium Blue Chlo-
ride (NBT-BCIP, Thermo Fisher Scientific GmbH, Dreieich, Germany) according to standard protocols (Data S6F).
Hamster model of SARS-CoV-2 infection
Animal procedures were performed according to the European Guidelines for Animal Studies after approval by the Institutional An-
imal Care Committee and the relevant state authority (Landesamt f€ur Gesundheit und Soziales, Berlin, Permit number 0086/20).
SARS-CoV-2 isolate BetaCoV/Germany/BavPat1/2020 (Wölfel et al., 2020) was used as challenge virus for hamster experiments.
The virus was propagated and titrated on Vero E6 cells (ATCC CRL-1586) in minimal essential medium (MEM; PAN Biotech, Aiden-
bach, Germany) supplemented with 10% fetal bovine serum (PAN Biotech), 100 IU/ml penicillin G and 100 mg/ml streptomycin (Carl
Roth, Karlsruhe, Germany) and stored at 80C prior to experimental infections.
Per group, nine male and female Syrian hamsters (Mesocricetus auratus) strain RjHAN:AURA (Janvier, Le Genest-Saint-Isle,
France) were used. Animals were housed in GR-900 IVC cages (Tecniplast, Buguggiate, Italy) and provided with food ad libidum
and bountiful enrichment and nesting materials (Carfil, Oud-Turnhout, Belgium). Hamsters were randomly distributed into experi-
mental groups and treated intraperitoneally with 3.7 mg/kg or 37 mg/kg STE90-C11 in a total volume of 1 mL PBS, two hours
post infection, the control group received 1 mL PBS only at the same time-point.
SARS-CoV-2 infection was performed as previously described (Osterrieder et al., 2020). Briefly, anaesthetized hamsters received
1x105 pfu SARS-CoV-2 in 60 mL MEM intranasally two hours before treatment. Following infection, the clinical presentation of all an-
imals was monitored twice a day, body weight of all hamsters was recorded daily. On days 3, 5 and 14 post infection, three randomly
assigned hamsters per group were euthanized. Euthanasia was applied by exsanguination under general anesthesia as described
(Nakamura et al., 2017). Oropharyngeal swabs and lungs were collected for virus titrations, RT-qPCR and/or histopathologicale6 Cell Reports 36, 109433, July 27, 2021
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logical investigations.
To assess virus titers from 50mg lung tissue, tissue homogenates were prepared using a beadmill (Analytic Jena) and 10-fold serial
dilutions were prepared in MEM, and plated on Vero E6 cells in 12-well-plates. The dilutions were removed after 2 h and cells were
overlaid with 1.25%microcrystalline cellulose (Avicel) in MEM supplemented with 10% FBS and penicillin/streptomycin. Three days
later, cells were formalin-fixed, stained with crystal violet, and plaques were counted.
Transgenic mice model of SARS-CoV-2 infection
All animal experiments were performed in compliance with the German Animal Welfare Act (TierSchG BGBl. I S. 1206, 1313; May 18,
2006) and Directive 2010/63/EU. The mice were handled in accordance with good animal practice as defined by the Federation for
Laboratory Animal Science Associations and Gesellschaft f€ur Versuchstierkunde/Society of Laboratory Animal Science. All animal
experiments were approved by the responsible state office (Lower Saxony State Office of Consumer Protection and Food Safety)
under permits number 20_3567. K18hACE2mice (B6.Cg-Tg(K18-ACE2)2Prlmn/J) were purchased fromCharles River (Sulzfeld, Ger-
many), Mice were housed at the animal facility of the Helmholtz Centre for Infection Research under pathogen-free conditions.
Mice were fixed in a restrainer before injection and the lateral tail veins were hyperaemized. Different antibody concentrations were
diluted in 100ul of PBS and injected intravenous into the lateral tail vein.
Female andmale at least 6-wk-old mice were infected with tissue culture– derived virus and housed in specific pathogen-free con-
ditions throughout the experiment. Mice were anesthetized with Ketamin/Xylazin and inoculated intranasally with 2,000 PFU of virus
in 20 ul of Phosphate buffered saline (PBS).
The mice were sacrificed by CO2 asphyxiation on day 5. Lungs were collected aseptically, homogenized in 500 mL PBS and stored
at 80◦C. Part of the organ homogenates were used for titration cells and the other part for qPCR Analysis. Organ homogenates
were serially diluted 1:10 – 1:105 in medium (DMEM supplemented with 5% FCS, 2 mM glutamine, 100 IU/mL penicillin and
100 mg/mL streptomycin). Vero E-6 cells were then inoculated with 200ul of diluted homogenates and incubated for 1h, 37C,
CO2 incubator. Cells were then coverd with 1.75% Carboxymethyl-cellulose and incubated at 37
C, CO2 incubator for 3-5 days.
Plates were then fixed with 6% Paraformaldehyde for 1h and then stained with 1% Crystal violet. Plaques were then read under
microscope.
In vitro evolution of SARS-CoV-2 by antibody co-cultivation
This assay was performed with STE90-C11 and Palivizumab as described by Baum et al. (2020).
Fab and RBD22 production for co-crystallization
The production of STE90-C11 Fab fragment was done by transient co-transfection of plasmids encoding the heavy and the light
chain in Expi293F cells cultivated at 37C, 5% CO2 and 100rpm in Expi Expression Medium. The transfection was performed at a
density of 3*10̂ 6 cells/ml by adding 1mg/ml culture mixed plasmids and 4 mg/ml culture PEI 40 kDa (Polyscience). The culture
was incubated for 72 hours according to the protocol. The supernatant was harvested by centrifugation (30min, 3000 g) and sterile
filtration (0.2mm). The Fab-fragment was purified by affinity chromatography using 1ml HisTrap Excel column (GE Healthcare) fol-
lowed by a size exclusion chromatography on a 10/300 Superdex200 Increase column (GE Healthcare) according to manufactures
manual.
For the production of RBD22 High Five cells grown in EX-CELL 405 serum-free medium (Sigma) were transiently transfected with
5mg/mL plasmid and 20mg/mL PEI 40 kDa (Polyscience) at a cell density of 5*10̂ 6 cells/ml. After 4h incubation at 27C and 100rpm
the cells were diluted 5-foldwith EX-CELLmedium to a density of 1*10̂ 6 cells/ml and further incubated for threemore days. Following
centrifugation (5000xg 30min) and sterile filtration (0.2mm) the supernatant was loaded on a 5ml HisTrap Excel column (GE Health-
care). After washing and elution with imidazole the RBD22 containing fractions were further purified by size exclusion chromatog-
raphy on a 26/600 Superdex 200 pg using 20mM Tris-HCl pH8 and 150mM NaCl as a buffer. Aliquots were snap-frozen in liquid
nitrogen and stored at 80C till further use.
Crystallization, data collection and structure determination
The Fab fragment of STE90-C11 was incubated overnight with a 1.2 molar excess of purified RBD22 at 4C. The complex was iso-
lated by size exclusion chromatography on a Superdex 200 Increase 10/300GL (GEHealthcare) with 20mMTris-HCl pH8 and 150mM
NaCl as a running buffer. Fractions containing the complex were concentrated utilizing a Vivaspin2 ultrafiltration unit (10,000MWCO;
Sartorius). Crystallizations trails were set up in 96-well sitting-drop vapor diffusion plates (Intelli 96-3 plates, Art Robbins Instruments)
with a pipetting robot (Crystal Gryphon, Art Robbins Instruments) mixing 200nl reservoir solution with 200nl of protein solution (14mg/
mL, 7mg/mL) and equilibrated against 60 mL of reservoir solution. As initial screens the Cryos Suite and the JCSGplus Suite (QIAGEN)
were chosen and crystal growth was monitored in a crystal hotel (RockImager, Formulatrix). Initial hits were further optimized by a
random screen assembled with a Formulator pipetting robot (Formulatrix). Best diffracting crystals grew in 13.3% (w/v) polyethylene
glycol 6,000, 0.1M MES pH 5.6 and 0.24M tri sodium citrate. Crystals were harvested with nylon loops and soaked in reservoir so-
lution mixed with 2,3-(R,R)-butandiol (Alfa Aeser) to a final concentration of 10% (v/v) prior to flash cooling in liquid nitrogen.Cell Reports 36, 109433, July 27, 2021 e7
Article
ll
OPEN ACCESS3600 diffraction images with an oscillation angle of 0.1 per image were collected at the beamline P11 at PETRA III (DESY,
Hamburg, Germany) (Burkhardt et al., 2016) on a Pilatus 6M fast detector (Dectris) and processed with XDS (Kabsch, 2010) and
Aimless (Evans and Murshudov, 2013) yielding a dataset with a resolution cut off of 2.0 Å based on a CC1/2 value greater than
0.5. Initial phases were determined by molecular replacement with Phaser (McCoy et al., 2007). As a search model the coordinates
of a Fab fragment and the RBDwas used (PDB: 7BWJ) (Ju et al., 2020). Themodel was further improved bymanual rebuilding in Coot
(Emsley et al., 2010) and computational refinement with phenix. refine (Afonine et al., 2012) including placement of water, TLS refine-
ment and riding hydrogens in the final steps of the procedure. Depictions of themodel were generatedwith PyMolmolecular graphics
system (Schrödinger LLC; version 2.3.2). Data processing and model refinement statistics can be found in Data S7A. The final model
can be accessed under the PDB code 7B3O.
QUANTIFICATION AND STATISTICAL ANALYSIS
The quantification and statistical analysis is indicated for each individual experiment in the figure legends and the material and
methods.e8 Cell Reports 36, 109433, July 27, 2021
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Supplementary Data 1: Analysis of the COVID-19 patient humoral immune answer (related to STAR Method “COVID-19 
convalescent patient library construction” and Figure 1). A) Serum titration of COVID-19 patients on SARS-CoV-2 proteins 
(related to STAR Method “COVID-19 convalescent patient library construction”). Titration ELISA on RBD. The ELISAs were made 





Supplementary  Data  2: Inhibition of the ACE2-spike interaction and  inhibition of SARS-CoV-2 (related to STAR Method
“Inhibition of S1-S2 and RBD binding to ACE2 expressing cells using flow cytometry” and Table 1). (A) IC50 determination by
flow cytometry using 10 nM RBD-mFc and 100 nM - 0.3 nM IgG. (B) IC50 determination by flow cytometry using 50 nM S1-S2-His
and 500 - 1.5 nM nM IgG. The binding is given in relation to the binding without the antibody. The inhibition assays were made as
single titrations.
Supplementary Data 3: Inhibition of the ACE2-spike interaction by STE90-C11 (related to table 1). IC50 determination by flow
cytometry using 10 nM RBD-mFc, respectively 50 nM S1-His and 100 nM - 0.1 nM IgG. Avelumab was used as negative control.
IC50 were calculated with OriginPro using the Logistic5 Fit.
Supplementary Data 4: Binding analysis of STE90-C11 and other anti-RBD antibodies (related to Figure 4). A) Cross-reactivity of STE90-C11 to other spike S1 subunits of SARS-CoV-1, MERS-CoV, HCov-HKU1, HCoV-229E and HCoV-NL63 analzyed by ELISA. S1-HIS
SARS-CoV-2 Hi5 was produced inhouse. S1-HIS SARS-CoV-2 HEK and all other coronaviruses S1 domain proteins were obtained commercially. B) Analysis of STE90-C11 on the RBD mutations V367F, N439K, G476S, V483A, E484K, G485R, F486V and these mutations in
combination  (7PM).  C) analysis  of  STE90-C11  on  the  mutants  K417N,  K417T,  L452R,  Y453F,  S477N,  N501Y,  L452R+D614G,  E484K+N501Y,  K417N+E484K+N501Y,  K417T+E484K+N501Y,  S1-S2  D614G,  S1-S2  B.1.1.7  complete
(Δ69/70+Δ144+N501Y+A570D+D614G+P681H+T716I+S982A+D1118H). D) Analysis of L452R+E484Q+D614G, E) Analysis of REGN10933, REGN10987, CR3022, CB6 on the RBD mutations V367F, N439K, G476S, V483A, E484K, G485R, F486V. All antibody binding







Supplementary Data 5: Cell based inhibition analysis of selected mutants (related to Figure 4). Flow cytometry using 10 nM S1-His, respectively the mutants, and 100 nM - 0.3 nM IgG to
analyze the inhibition of S1 binding to ACE2 presenting cells. The binding is given in relation to the binding without the antibody. The inhibition assays were performed in triplicates, mean ±
s.e.m. are given.
Supplementary Data 6: Biochemical characterization of STE90-C11 (related to Figure 4-6,  STAR Method “Affinity measurement by Bio-Layer Interferometry” and "Immunoblot analysis"). A) SEC profiles under different stress conditions of the STE90-C11 antibody 
(0.3 mg/mL IgG). B) Specificity assay of the STE90-C11 compared to IVIG and Paviluzumab normalized to Avelumab. BLI measurements were performed in three setups: C) 1. anti-mFc capture tip, 2. RBD-mFc, 3. STE90-C11 Fab. D) 1. Fab2G capture tip, 2. STE90-C11 IgG, 3. 
S1-His. E) 1. protein A tip, 2. STE90-C11 IgG, 3. S1-His. BLI experiments were analzyed using the Octet qKe Data Analysis HT 11.0 software and a 1:1 binding model. F) Immunoblot of STE90-C11 on RBD-His under reducing and non-reducing conditions heated at 95°C or 56°C.










Resolution range 48.1 - 2.0 (2.05 - 2.0)
Space group C 1 2 1
Unit cell 195.8 87.4 57.1 90 100.6 90
Total reflections 437879 (30207)
Unique reflections 63906 (4501)
Multiplicity 6.9 (6.7)








Resolution range 47.58 - 2.0 (2.07 - 2.0)
Reflections used in refinement 63849 (6335)
Reflections used for Rfree 1088 (109)
Rwork 0.1850 (0.3236)
Rfree 0.2243 (0.3706)
Number of non-hydrogen atoms 5196
  macromolecules 4741
  ligands 28




Ramachandran favored (%) 97,69
Ramachandran allowed (%) 2,31
Ramachandran outliers (%) 0
Rotamer outliers (%) 0,75
Clashscore 2,14
Average B-factor 43,01
  macromolecules 42,63
  ligands 103,87
  solvent 43,17
B
Total [Å2] VH [Å2] VL [Å2]
ACE2 843.3 n.a. n.a
STE90-C11 1132.9 668.7 464.2
CB6 1078.3 734.3 344
B38 1207.7 712.7 495
CR3022 1007.4 592.7 414.7
REGN10933 933.7 754.5 179.2
REGN10987 606.8 497.2 109.6
BD-368-2 1135.2 740.7 394.5
Supplementary Data 7: Data on the STE90-C11-RBD complex and superposition of the STE90-C11:SARS-CoV-2 RBD complex (related to Figure 6). A) Crystallization dataset of the 
STE90-C11-RBD22 complex. B) Antibody-RDB, respectively ACE2-RBD, interface areas according analyzed using "Protein interfaces, surfaces and assemblies" (PISA) at the European 
Bioinformatics Institute (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html). C) Model onto cryo-EM models of the whole SARS-CoV-2 spike protein (Walls et al., 2020).
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